DSM ComfortCoat® Hydrophilic Coating Utilized in New Drug Eluting Stent Delivery System from CID SpA

BERKELEY,
Calif.–(BUSINESS WIRE)–DSM, a
global leader in biomedical materials science, today announced the use of its
ComfortCoat® hydrophilic coating on the delivery system of CID SpAs new Cre8™
Drug Eluting Stent (DES), CE marked the 16th of July 2011.

“As DSMs materials portfolio continues to expand with novel
coating materials, the successful launch of Cre8 DES is another strong
testament to the value we provide medical device manufacturers across the
globe.”

CID SpA chose ComfortCoat® hydrophilic coating, a
proprietary DSM product and technology, since it facilitates the treatment of
more complex patient anatomies by enhancing the deliverability of its
stentdelivery systems during percutaneous coronary intervention procedures.

Recently released data has not only proven the unmatched
effectiveness of Cre8™ DES in patients with coronary artery disease, but
showcases the potential for this type of drug eluting stent system to help
physicians shorten the dual antiplatelet therapy period for their
patients.Further, CID is leveraging the latest advanced delivery system
technologies, particularly the ComfortCoat® hydrophilic coating, in order to
maximize acute device performances.

“The launch of Cre8 DES aligns with our mission of supporting
interventional cardiologists and their patients with the development of
innovative systems that positively impact patient outcomes, in terms of
efficacy and safety, while also helping to reduce costs within the healthcare
delivery system,” said Franco Vallana, president and CEO of CID SpA. “By
collaborating with DSM, we are able to ensure interventional cardiologists
receive the benefits of the worlds most advanced technologies within our drug
eluting stent systems.”

“Our long-standing partnership with CID reaffirms our
continued commitment to providing innovative material solutions for the
cardiovascular market, which, ultimately, help to lower patient risk and
improve procedural outcomes,” said John Marugg, Business Manager Coatings, DSM
Biomedical. “As DSMs materials portfolio continues to expand with novel
coating materials, the successful launch of Cre8 DES is another strong
testament to the value we provide medical device manufacturers across the
globe.”

This announcement precedes the start of COMPAMED, where DSM
will be exhibiting in Hall 8a at booth K28 from November 16-18, 2011 in Düsseldorf, Germany.

DSM – Bright Science. Brighter Living.™

Royal DSM N.V. is a global science-based company active in
health, nutrition and materials. By connecting its unique competences in Life
Sciences and Materials Sciences DSM is driving economic prosperity,
environmental progress and social advances to create sustainable value for all
stakeholders. DSM delivers innovative solutions that nourish, protect and
improve performance in global markets such as food and dietary
supplements,personal care, feed, pharmaceuticals, medical devices, automotive,
paints, electrical and electronics, life protection, alternative energy and
bio-based materials. DSMs 22,000 employees deliver annual net sales of about €
9 billion. The company is listed on NYSE Euronext. More information can be
found at www.dsm.com.

CID SpA

CID (Carbostent & Implantable Devices) is dedicated to contributing to
human welfare by improving the quality of patient care and after-care through
the development of innovative, minimally invasive implantable devices,
procedures and therapies. A strong background in the field of implantable
cardiovascular devices and haemocompatible materials, expressed in a remarkable
IP portfolio, and a management with an expertise gained in many years of
research, development and clinical experience, allow CID to offer the investors
a fair return and its customers the necessary tools to meet new challenges.

ComfortCoat® is a registered trademark of Royal DSM N.V.

Cre8™ is a trademark of CID SpA.